FATE THERAPEUTICS INC Research and Development Expense
FATE THERAPEUTICS INC (FATE) reported Research and Development Expense of $24.39 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-13
- FATE THERAPEUTICS INC research and development expense for the quarter ending 2026-06-30 was $24.39M, a 11.09% decline year-over-year.
- FATE THERAPEUTICS INC research and development expense for the quarter ending 2026-03-31 was $24.70M, a 15.21% decline year-over-year.
- FATE THERAPEUTICS INC research and development expense for the quarter ending 2025-12-31 was $25.43M, a 24.35% decline year-over-year.
- FATE THERAPEUTICS INC research and development expense for the quarter ending 2025-09-30 was $25.84M, a 25.43% decline year-over-year.
- FATE THERAPEUTICS INC research and development expense for fiscal 2025 was $107.83M, a 20.13% decline from fiscal 2024.
- FATE THERAPEUTICS INC research and development expense for fiscal 2024 was $135.00M, a 21.78% decline from fiscal 2023.
- FATE THERAPEUTICS INC research and development expense for fiscal 2023 was $172.60M, a 46.14% decline from fiscal 2022.
- FATE THERAPEUTICS INC research and development expense for fiscal 2022 was $320.45M, a 48.69% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month | Research and Development Expense 77 month | Research and Development Expense 80 month | Research and Development Expense 83 month |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $24.39M 10-Q · filed 2026-08-13 | $49.09M 10-Q · filed 2026-08-13 | $74.52M derived: sum of 3 quarters · filed 2026-08-13 | $100.35M derived: sum of 4 quarters · filed 2026-08-13 | |||
| 2026-03-31 | $24.70M 10-Q · filed 2026-05-13 | $50.13M derived: sum of 2 quarters · filed 2026-05-13 | $75.97M derived: sum of 3 quarters · filed 2026-05-13 | $103.40M derived: sum of 4 quarters · filed 2026-08-13 | |||
| 2025-12-31 | $25.43M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $51.26M derived: sum of 2 quarters · filed 2026-02-26 | $78.69M derived: sum of 3 quarters · filed 2026-08-13 | $107.83M 10-K · filed 2026-02-26 | |||
| 2025-09-30 | $25.84M 10-Q · filed 2025-11-13 | $53.27M derived: sum of 2 quarters · filed 2026-08-13 | $82.40M 10-Q · filed 2025-11-13 | $116.01M derived: sum of 4 quarters · filed 2026-08-13 | |||
| 2025-06-30 | $27.43M 10-Q · filed 2026-08-13 | $56.57M 10-Q · filed 2026-08-13 | $90.17M derived: sum of 3 quarters · filed 2026-08-13 | $124.83M derived: sum of 4 quarters · filed 2026-08-13 | |||
| 2025-03-31 | $29.14M 10-Q · filed 2026-05-13 | $62.74M derived: sum of 2 quarters · filed 2026-05-13 | $97.39M derived: sum of 3 quarters · filed 2026-05-13 | $132.00M derived: sum of 4 quarters · filed 2026-05-13 | |||
| 2024-12-31 | $33.61M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $68.26M derived: sum of 2 quarters · filed 2026-02-26 | $102.86M derived: sum of 3 quarters · filed 2026-02-26 | $135.00M 10-K · filed 2026-02-26 | |||
| 2024-09-30 | $34.65M 10-Q · filed 2025-11-13 | $69.25M derived: sum of 2 quarters · filed 2025-11-13 | $101.39M 10-Q · filed 2025-11-13 | $133.21M derived: sum of 4 quarters · filed 2025-11-13 | |||
| 2024-06-30 | $34.60M 10-Q · filed 2025-08-12 | $66.74M 10-Q · filed 2025-08-12 | $98.56M derived: sum of 3 quarters · filed 2025-08-12 | $132.83M derived: sum of 4 quarters · filed 2025-08-12 | |||
| 2024-03-31 | $32.14M 10-Q · filed 2025-05-13 | $63.95M derived: sum of 2 quarters · filed 2025-05-13 | $98.23M derived: sum of 3 quarters · filed 2025-05-13 | $139.10M derived: sum of 4 quarters · filed 2025-05-13 | |||
| 2023-12-31 | $31.82M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-05 | $66.09M derived: sum of 2 quarters · filed 2025-03-05 | $106.97M derived: sum of 3 quarters · filed 2025-03-05 | $172.60M 10-K · filed 2025-03-05 | |||
| 2023-09-30 | $34.27M 10-Q · filed 2024-11-12 | $75.15M derived: sum of 2 quarters · filed 2024-11-12 | $140.78M 10-Q · filed 2024-11-12 | $227.97M derived: sum of 4 quarters · filed 2024-11-12 | |||
| 2023-06-30 | $40.88M 10-Q · filed 2024-08-13 | $106.50M 10-Q · filed 2024-08-13 | $193.70M derived: sum of 3 quarters · filed 2024-08-13 | $273.51M derived: sum of 4 quarters · filed 2024-08-13 | |||
| 2023-03-31 | $65.63M 10-Q · filed 2024-05-09 | $152.82M derived: sum of 2 quarters · filed 2024-05-09 | $232.64M derived: sum of 3 quarters · filed 2024-05-09 | $313.94M derived: sum of 4 quarters · filed 2024-05-09 | |||
| 2022-12-31 | $87.19M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | $167.01M derived: sum of 2 quarters · filed 2024-02-26 | $248.31M derived: sum of 3 quarters · filed 2024-02-26 | $320.45M 10-K · filed 2024-02-26 | |||
| 2022-09-30 | $79.82M 10-Q · filed 2023-11-08 | $161.12M derived: sum of 2 quarters · filed 2023-11-08 | $233.26M 10-Q · filed 2023-11-08 | $302.78M derived: sum of 4 quarters · filed 2023-11-08 | |||
| 2022-06-30 | $81.31M 10-Q · filed 2023-08-08 | $153.45M 10-Q · filed 2023-08-08 | $222.96M derived: sum of 3 quarters · filed 2023-08-08 | $276.09M derived: sum of 4 quarters · filed 2023-08-08 | |||
| 2022-03-31 | $72.14M 10-Q · filed 2023-05-03 | $141.65M derived: sum of 2 quarters · filed 2023-05-03 | $194.78M derived: sum of 3 quarters · filed 2023-05-03 | $242.81M derived: sum of 4 quarters · filed 2023-05-03 | |||
| 2021-12-31 | $69.52M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $122.64M derived: sum of 2 quarters · filed 2023-02-28 | $170.67M derived: sum of 3 quarters · filed 2023-02-28 | $215.52M 10-K · filed 2023-02-28 | |||
| 2021-09-30 | $53.13M 10-Q · filed 2022-11-03 | $101.15M derived: sum of 2 quarters · filed 2022-11-03 | $146.00M 10-Q · filed 2022-11-03 | $184.99M derived: sum of 4 quarters · filed 2023-02-28 | |||
| 2021-06-30 | $48.02M 10-Q · filed 2022-08-03 | $92.87M 10-Q · filed 2022-08-03 | $131.86M derived: sum of 3 quarters · filed 2023-02-28 | $162.55M derived: sum of 4 quarters · filed 2023-02-28 | |||
| 2021-03-31 | $44.85M 10-Q · filed 2022-05-04 | $83.83M derived: sum of 2 quarters · filed 2023-02-28 | $114.53M derived: sum of 3 quarters · filed 2023-02-28 | $141.20M derived: sum of 4 quarters · filed 2023-02-28 | |||
| 2020-12-31 | $38.98M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $69.68M derived: sum of 2 quarters · filed 2023-02-28 | $96.34M derived: sum of 3 quarters · filed 2023-02-28 | $125.62M 10-K · filed 2023-02-28 | |||
| 2020-09-30 | $30.69M 10-Q · filed 2021-11-04 | $57.36M derived: sum of 2 quarters · filed 2021-11-04 | $86.64M 10-Q · filed 2021-11-04 | $111.85M derived: sum of 4 quarters · filed 2022-02-28 | |||
| 2020-06-30 | $26.67M 10-Q · filed 2021-08-04 | $55.95M 10-Q · filed 2021-08-04 | $81.16M derived: sum of 3 quarters · filed 2022-02-28 | $104.36M derived: sum of 4 quarters · filed 2022-02-28 | |||
| 2020-03-31 | $29.28M 10-Q · filed 2021-05-05 | $54.49M derived: sum of 2 quarters · filed 2022-02-28 | $77.69M derived: sum of 3 quarters · filed 2022-02-28 | $99.32M derived: sum of 4 quarters · filed 2022-02-28 | |||
| 2019-12-31 | $25.21M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $48.41M derived: sum of 2 quarters · filed 2022-02-28 | $70.04M derived: sum of 3 quarters · filed 2022-02-28 | $87.77M 10-K · filed 2022-02-28 | |||
| 2019-09-30 | $23.20M 10-Q · filed 2020-11-05 | $44.83M derived: sum of 2 quarters · filed 2020-11-05 | $62.56M 10-Q · filed 2020-11-05 | $76.66M derived: sum of 4 quarters · filed 2021-02-24 | |||
| 2019-06-30 | $21.63M 10-Q · filed 2020-08-05 | $39.36M 10-Q · filed 2020-08-05 | $53.45M derived: sum of 3 quarters · filed 2021-02-24 | $67.09M derived: sum of 4 quarters · filed 2021-02-24 | |||
| 2019-03-31 | $17.73M 10-Q · filed 2020-05-11 | $31.82M derived: sum of 2 quarters · filed 2021-02-24 | $45.46M derived: sum of 3 quarters · filed 2021-02-24 | $62.28M derived: sum of 4 quarters · filed 2021-02-24 | |||
| 2018-12-31 | $14.10M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-24 | $27.73M derived: sum of 2 quarters · filed 2021-02-24 | $44.55M derived: sum of 3 quarters · filed 2021-02-24 | $56.02M 10-K · filed 2021-02-24 | |||
| 2018-09-30 | $13.64M 10-Q · filed 2019-11-05 | $30.45M derived: sum of 2 quarters · filed 2019-11-05 | $41.93M 10-Q · filed 2019-11-05 | $51.82M derived: sum of 4 quarters · filed 2020-03-02 | |||
| 2018-06-30 | $16.82M 10-Q · filed 2019-08-06 | $28.29M 10-Q · filed 2019-08-06 | $38.18M derived: sum of 3 quarters · filed 2020-03-02 | $46.76M derived: sum of 4 quarters · filed 2020-03-02 | |||
| 2018-03-31 | $11.48M 10-Q · filed 2019-05-07 | $21.36M derived: sum of 2 quarters · filed 2020-03-02 | $29.94M derived: sum of 3 quarters · filed 2020-03-02 | $37.87M derived: sum of 4 quarters · filed 2020-03-02 | |||
| 2017-12-31 | $9.89M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | $18.46M derived: sum of 2 quarters · filed 2020-03-02 | $26.39M derived: sum of 3 quarters · filed 2020-03-02 | $34.36M 10-K · filed 2020-03-02 | |||
| 2017-09-30 | $8.58M 10-Q · filed 2018-11-01 | $16.50M derived: sum of 2 quarters · filed 2018-11-01 | $24.47M 10-Q · filed 2018-11-01 | $30.70M derived: sum of 4 quarters · filed 2019-03-05 | |||
| 2017-06-30 | $7.93M 10-Q · filed 2018-08-06 | $15.89M 10-Q · filed 2018-08-06 | $22.12M derived: sum of 3 quarters · filed 2019-03-05 | $28.93M derived: sum of 4 quarters · filed 2019-03-05 | |||
| 2017-03-31 | $7.97M 10-Q · filed 2018-05-10 | $14.20M derived: sum of 2 quarters · filed 2019-03-05 | $21.00M derived: sum of 3 quarters · filed 2019-03-05 | $27.78M derived: sum of 4 quarters · filed 2019-03-05 | |||
| 2016-12-31 | $6.23M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-05 | $13.03M derived: sum of 2 quarters · filed 2019-03-05 | $19.82M derived: sum of 3 quarters · filed 2019-03-05 | $26.45M 10-K · filed 2019-03-05 | |||
| 2016-09-30 | $6.80M 10-Q · filed 2017-11-01 | $13.59M derived: sum of 2 quarters · filed 2017-11-01 | $20.22M 10-Q · filed 2017-11-01 | $25.66M derived: sum of 4 quarters · filed 2018-03-05 | |||
| 2016-06-30 | $6.78M 10-Q · filed 2017-08-14 | $13.42M 10-Q · filed 2017-08-14 | $18.85M derived: sum of 3 quarters · filed 2018-03-05 | $23.85M derived: sum of 4 quarters · filed 2018-03-05 | |||
| 2016-03-31 | $6.64M 10-Q · filed 2017-05-15 | $12.07M derived: sum of 2 quarters · filed 2018-03-05 | $17.07M derived: sum of 3 quarters · filed 2018-03-05 | $21.93M derived: sum of 4 quarters · filed 2018-03-05 | |||
| 2015-12-31 | $5.43M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-05 | $10.44M derived: sum of 2 quarters · filed 2018-03-05 | $15.29M derived: sum of 3 quarters · filed 2018-03-05 | $19.86M 10-K · filed 2018-03-05 | |||
| 2015-09-30 | $5.00M 10-Q · filed 2016-11-07 | $9.86M derived: sum of 2 quarters · filed 2016-11-07 | $14.43M 10-Q · filed 2016-11-07 | $18.29M derived: sum of 4 quarters · filed 2017-03-16 | |||
| 2015-06-30 | $4.86M 10-Q · filed 2016-08-08 | $9.43M 10-Q · filed 2016-08-08 | $13.29M derived: sum of 3 quarters · filed 2017-03-16 | $17.37M derived: sum of 4 quarters · filed 2017-03-16 | |||
| 2015-03-31 | $4.57M 10-Q · filed 2016-05-09 | $8.43M derived: sum of 2 quarters · filed 2017-03-16 | $12.51M derived: sum of 3 quarters · filed 2017-03-16 | $16.48M derived: sum of 4 quarters · filed 2017-03-16 | |||
| 2014-12-31 | $3.87M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-16 | $7.95M derived: sum of 2 quarters · filed 2017-03-16 | $11.91M derived: sum of 3 quarters · filed 2017-03-16 | $16.43M 10-K · filed 2017-03-16 | |||
| 2014-09-30 | $4.08M 10-Q · filed 2015-11-03 | $8.05M derived: sum of 2 quarters · filed 2015-11-03 | $12.57M 10-Q · filed 2015-11-03 | $15.60M derived: sum of 4 quarters · filed 2016-03-03 | |||
| 2014-06-30 | $3.97M 10-Q · filed 2015-08-05 | $8.49M 10-Q · filed 2015-08-05 | $11.52M derived: sum of 3 quarters · filed 2016-03-03 | $14.90M derived: sum of 4 quarters · filed 2016-03-03 | |||
| 2014-03-31 | $4.52M 10-Q · filed 2015-05-07 | $7.55M derived: sum of 2 quarters · filed 2016-03-03 | $10.93M derived: sum of 3 quarters · filed 2016-03-03 | $14.00M derived: sum of 4 quarters · filed 2016-03-03 | $61.51M 10-Q · filed 2014-05-13 | ||
| 2013-12-31 | $3.03M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-03 | $6.41M derived: sum of 2 quarters · filed 2016-03-03 | $9.48M derived: sum of 3 quarters · filed 2016-03-03 | $12.01M 10-K · filed 2016-03-03 | $56.99M 10-K · filed 2014-03-17 | ||
| 2013-09-30 | $3.38M 10-Q · filed 2014-11-12 | $6.45M derived: sum of 2 quarters · filed 2014-11-12 | $8.98M 10-Q · filed 2014-11-12 | $12.38M derived: sum of 4 quarters · filed 2015-03-12 | $53.95M 10-Q · filed 2013-11-13 | ||
| 2013-06-30 | $3.07M 10-Q · filed 2014-08-12 | $5.60M 10-Q · filed 2014-08-12 | $9.00M derived: sum of 3 quarters · filed 2015-03-12 | $12.32M derived: sum of 4 quarters · filed 2015-03-12 | |||
| 2013-03-31 | $2.53M 10-Q · filed 2014-05-13 | $5.93M derived: sum of 2 quarters · filed 2015-03-12 | $9.25M derived: sum of 3 quarters · filed 2015-03-12 | ||||
| 2012-12-31 | $3.40M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-12 | $6.72M derived: sum of 2 quarters · filed 2015-03-12 | $12.00M 10-K · filed 2015-03-12 | ||||
| 2012-09-30 | $3.31M 10-Q · filed 2013-11-13 | $8.60M 10-Q · filed 2013-11-13 | |||||
| 2011-12-31 | $9.86M 10-K · filed 2014-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |